965.7000 -34.90 (-3.49%)
NSE Aug 04, 2025 15:31 PM
Volume: 128.1K
 

BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Alivus Life Sciences.. has an average target of 1317.00 from 1 broker.
More from Alivus Life Sciences Ltd.
All Rapid Results
Recommended